เว็บไซต์คืออะไร?

http://www.GreenCultureLabs-Thailand.com/

Green Culture Labs co., Ltd, Amphoe Wat Bot (2025)

03/11/2025

Multi-Therapeutic Potential of Mitragyna speciosa (Kratom) Alkaloids

2025 Review Summary
(Begum et al., 2025 — ScienceDirect, DOI S2307410825000252)

✔️ Overview

• 2025 review compiles 150 + studies on chemistry, pharmacology, extraction, and safety of Mitragyna speciosa.

• Focuses on mitragynine and 7-hydroxymitragynine with attention to minor alkaloids and combined bioactivity.

• Purpose — clarify therapeutic promise and research gaps for clinical, regulatory, and industrial advancement.

✔️ Phytochemistry and Extraction

• Mitragynine makes up 40–66 % of total alkaloids; 7-hydroxymitragynine occurs in trace amounts but has far greater μ-opioid potency.

• Over 50 additional alkaloids identified (speciociliatine, paynantheine, mitraphylline, corynantheidine).

• Alkaloid profiles shift with leaf age, origin, drying, solvent, pH, and temperature.

• Authors call for green, scalable extraction methods adaptable to GMP and pharma production.

✔️ Pharmacological Findings

• Mitragynine acts as partial μ-opioid agonist with adrenergic and serotonergic modulation — stimulant at low dose, analgesic at higher dose.

• Recent Preclinical studies show’s Mitragynine did not have respiratory suppression and may increase breathing under certain circumstances.

• 7-Hydroxymitragynine is a potent μ-agonist responsible for most analgesic strength in vivo.

• Documented activities include analgesic, anti-inflammatory, antioxidant, antidepressant, neuroprotective, anti-addictive, and antitumour effects.

• Human data remain limited; most evidence is pre-clinical.

• Both alkaloids show G-protein-biased agonism with reduced β-arrestin recruitment, suggesting lower respiratory risk.

✔️ Safety and Toxicology

• Adverse effects include dependence, hepatic and cardiovascular stress.

• Toxicity often linked to poly-alkaloid mixtures or adulterants rather than pure compounds.

• Oxidative conversion of mitragynine → 7-OH demands stability and impurity control. (RnD requires maximum purity for control effects)

• Comprehensive toxicology and dose-controlled clinical trials are required.

✔️ Analytical and Quality Control

• Lack of standardised quantification hampers comparability.

• HPLC-DAD and LC-MS/MS recommended with full ICH Q2(R1) validation.

• Fingerprinting via LC-HRMS supports authenticity and batch consistency.

• Stability testing under ICH Q1A(R2) should track degradation and oxidation.

• Reference materials for major and minor alkaloids are essential for GMP manufacture.

✔️ Research Gaps and Future Work

• Profile roots, stems, flowers, under-studied plant parts.

• Link chemotype to bioactivity and safety via integrated metabolomics and toxicology.

• Design validated human dose-response trials to define therapeutic margin and dependence risk.

• Adopt computational modeling and in-silico ADMET for new analogue screening.

• Develop international reference libraries and SOP alignment for regulators.

✔️ Key Takeaway

Mitragyna speciosa shows diverse alkaloids with promising multi-therapeutic effects.

Translating this potential demands GMP-standardised chemistry, validated analytics, and rigorous clinical evidence before mainstream pharmaceutical use.

Source to 2025 Study Here ⬇️

A review on multi-therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine: Experimental evidence and future perspectives

https://www.sciencedirect.com/science/article/pii/S2307410825000252

30/10/2025

Medicinal Plants Targeting the Five Primary Physiological Pathways of Pain

Pain affects how we think feel and connect with others making it one of the most disruptive health challenges worldwide.

Modern research continues to highlight how natural plant compounds can effectively target pain pathways while minimizing the side effects often seen with synthetic drugs

✔️ Key Findings

• Scientists have identified multiple medicinal plants that act on the body’s natural pain control systems including the opioid serotonergic and endocannabinoid networks

• These botanicals contain bioactive compounds that interact with receptors in the brain and nerves helping to reduce inflammation calm pain signaling and restore emotional balance

• The 2025 Phytotherapy Research review emphasizes that multimodal botanical agents can deliver clinically meaningful pain relief through mechanisms overlapping with pharmaceutical opioids antidepressants and anti inflammatory drugs but with improved safety and tolerance profiles

✔️ Leading Medicinal Plants and Their Mechanisms

• Kratom (Mitragyna speciosa)
Activates μ opioid receptors and α2 adrenergic pathways producing analgesia comparable to morphine but with a ceiling/adverse effects such as respiratory depression, constipation, and physical dependency.

• Psilocybin (Psilocybe spp.)
Targets 5 HT2A serotonergic receptors promoting neuroplasticity and emotional reframing of chronic pain while modulating perception and mood

• Cannabis (Cannabis sativa)
Stimulates CB1 and CB2 receptors of the endocannabinoid system reducing neuropathic and inflammatory pain while improving stress and sleep regulation

• Turmeric (Curcuma longa)
Curcumin inhibits NF κB transcription factor and desensitizes TRPV1 pain receptors leading to potent anti inflammatory antioxidant and neuroprotective effects

• Capsaicin (Capsicum annuum) Repeatedly activates and then desensitizes TRPV1 receptors decreasing localized nerve pain and hypersensitivity

• White Willow (Salix alba)
Contains salicin which converts into salicylic acid to inhibit COX enzymes and block prostaglandin synthesis reducing inflammation and swelling

✔️ Why It Matters

• These plant compounds act on the same biological systems as many prescription drugs but with lower toxicity and reduced potential for dependence

• Their ability to engage multiple receptor systems simultaneously makes them ideal for complex pain syndromes such as neuropathic fibromyalgic and inflammatory pain

• Combining traditional botanical wisdom with modern pharmacology can guide the creation of standardized botanical medicines offering safer long term solutions

✔️ Takeaway

Nature remains one of the richest sources of safe effective and affordable pain treatments. Understanding how these plants interact with human receptor networks allows the development of next generation analgesics that unite traditional knowledge and scientific precision

October 22, 2025

Source to Study Here ⬇️

Plant-Derived Compounds: A Potential Treasure for Development of Analgesic and Antinociceptive Therapeutics.

October 22, 2025

https://onlinelibrary.wiley.com/doi/abs/10.1002/ptr.70113

25/10/2025

Global wastewater study finds Kratom Alkaloid Mitragynine to be the world’s most detected new psychoactive substance (NPS).

• An international research team analyzed wastewater from 52 treatment plants across 20 countries covering more than 20 million people to identify new psychoactive substances (NPS)

• Advanced LC-MS/MS and solid-phase extraction methods detected 21 new psychoactive compounds including plant alkaloids, synthetic cathinones, benzodiazepines, opioids, and dissociatives

✔️ Mitragynine, the primary alkaloid from Mitragyna speciosa (kratom), was the most frequently detected compound appearing at 38 of 55 global sites and showing the highest population-normalized mass loads

• This marks the first time a natural plant alkaloid surpassed synthetic designer drugs such as 3-MMC and eutylone in global surveillance studies

✔️ 3-MMC and eutylone ranked next followed by synthetic opioids and benzodiazepines including protonitazene and bromazolam

✔️ Synthetic opioid protonitazene was detected in the United States confirming the international spread of potent nitazene analogues similar in effect to fentanyl.

• 2020 NIH stats with 20 Million active Kratom users in America alone, it’s now 2025.

• Cannabis, Co***ne and traditional opioids like morphine were not directly measured in this study but are monitored through separate international wastewater programs

✔️ The research validated long-term sample stability for up to four months at −20 °C enabling consistent intercontinental testing and comparison

• Analysis of European data showed a clear decline in 3-MMC following new legislation introduced between 2022 and 2023 demonstrating how wastewater data can track policy impact in real time

✔️ List of detected compounds from highest to lowest prevalence:

•Mitragynine
•3-Methylmethcathinone (3-MMC)
•Eutylone
•Mephedrone
•N,N-Dimethylpentylone
•Pentylone
•3,4-Methylenedioxy-PV8
•Bromazolam
•Desalkylflurazepam
•Flubrotizolam
•Flubromazolam
•Etizolam
•2F-DCK (2-Fluorodeschloroketamine)
•2-Oxo-PCE
•Hydroxetamine
•Protonitazene
•3-Chlorophenmetrazine
•Phenibut
•Alpha-D2PV
•Butylone and Dibutylone

✔️ Key insight

Mitragynine’s detection in multiple continents highlights kratom’s growing global use as a natural psychoactive substance and its emergence as a new class within wastewater epidemiology

• Wastewater analysis continues to prove its value as a global early-warning system connecting laboratory science, drug-policy evaluation, and public-health monitoring

✔️ Takeaway

• Mitragynine has overtaken synthetic stimulants as the most prevalent psychoactive compound detected in wastewater worldwide. Its rise shows the expanding role of natural alkaloids in modern psychoactive markets and the need for ongoing regulatory, clinical, and quality-control research.

New Psychoactive Substance (NPS) in global wastewater indicates widespread Kratom Consumption across multiple continents. It shows Kratom’s transition from regional Southeast Asian use to Global Exposure.

Published Date:
October 21, 2025

Source to Study Here:

https://www.sciencedirect.com/science/article/pii/S0043135425017506

24/10/2025

Spain Approves Hospital-Only Medicinal Cannabis Law

Spain has officially approved a new regulatory framework for medicinal cannabis, limiting its use to hospital settings under strict specialist oversight.

• Only hospital pharmacies can formulate and dispense medical cannabis

• Only specialist doctors are allowed to prescribe cannabis, not general practitioners

• AEMPS (Spanish medicines agency) will define each product’s approved indication, dosage and formulation through official monographs

• Cannabis formulas must be standardised preparations with defined THC and CBD content

• Preparations over 0.2% THC face tighter restrictions and controlled substance tracking

• All supply chain actors must maintain full documentation, GMP-style traceability and quality control

• Manufacturers must apply to AEMPS and prove their formulations meet standardisation and safety requirements

• Likely starting indications include MS-related spasticity, refractory epilepsy, chemotherapy-induced nausea, and chronic pain

• Over-the-counter sales remain prohibited under this law, which applies only to hospital use

• Future expansion of indications is possible based on scientific evidence and new monographs

✔️ This model emphasizes safety, medical oversight and pharmaceutical-grade quality control, setting a high regulatory bar for cannabis as a true medicine.

Cannabis flowers (raw plant material for smoking or vaporization) are not allowed.

Royal Decree (Real Decreto) approved by the Spanish government on October 7, 2025

Full Article Here ⬇️

——————————————
https://elpais.com/sociedad/2025-10-07/el-gobierno-aprueba-el-uso-del-cannabis-medicinal-solo-en-hospitales-y-recetado-por-especialistas.html

22/10/2025

Carvone (Spices) Conversion into CBD Cannabidiol enantiomers: as Novel Anticonvulsants

✔️ Carvone is a natural monoterpene found in Caraway, Dill, and Spearmint, used as a chiral precursor in synthesizing menthol, antiviral agents, and other pharmaceutical intermediates.

• Researchers have successfully transformed carvone (derived from caraway seeds) natural monoterpene into pure CBD-like compounds using a five-step synthetic process

• This approach replaces the cannabis plant as the source of cannabidiol by starting from a non-cannabis botanical compound and reconstructing its active molecular framework through controlled synthesis

• The process ensures total control over stereochemistry, purity, and potency while eliminating THC contamination and agricultural variability

• Among all analogues tested, the long-chain CBD variant demonstrated strong anticonvulsant effects in animal seizure models with no sedation or motor impairment

• Development of these carvone-based CBD molecules could provide safer, more stable pharmaceutical alternatives for treating resistant epilepsies and neurological disorders.

Carvone-based CBD represents a strategic opportunity for nations to pursue cannabinoid-inspired therapies without legal or agricultural dependence on cannabis or h**p.

✔️ Feasibility Implications and Implementation

• Carvone-derived synthetic CBD is more feasible and regulator-friendly (non-narcotic cannabinoids), compared to cultivation of Cannabis Sativa L.(A prohibited Plant in many countries)

• The Carvone-derived CBD analogue may serve as a potential chemical intermediate for synthesizing other cannabinoids through further synthetic modification, although no research has yet confirmed or demonstrated this pathway.

Published:
September 24, 2025

Source Here ⬇️

Carvone derived cannabidiol enantiomers as novel anticonvulsants.

https://www.nature.com/articles/s41386-025-02220-1

22/10/2025

Malaysia opens pathway for cannabis-based medical products

• The Ministry of Health Malaysia has officially opened the door for companies and researchers to register cannabis-based products for medical use

• Applicants must provide sufficient scientific evidence proving the safety, quality, and efficacy of cannabis-derived compounds before approval

• Cannabis remains regulated under the Dangerous Drugs Act 1952 and the Poisons Act 1952 meaning strict compliance with existing drug and poison control laws is required

• The decision does not legalize recreational use but creates a regulated route for scientifically validated cannabis formulations to enter the healthcare system

• The announcement came through a written parliamentary reply by Dr Kelvin Yii Lee Wuen who asked if medical ma*****na would be allowed in Malaysia

• The Ministry confirmed that all activities related to importation, sale, possession, or supply of cannabis remain prohibited unless authorized for approved medical or research purposes.

• This marks a major policy shift toward evidence-based evaluation rather than blanket prohibition of cannabis in Malaysia’s healthcare

• For botanical extract researchers and manufacturers this creates opportunity to develop GMP-standard cannabis extracts backed by analytical data from HPLC, GC-MS, and NMR testing

• Thailand’s current medical cannabis GMP producers may have opportunities to assist our neighboring country starting their own medicinal cultivation and processing.

• Scientific and regulatory readiness will determine which companies can move fastest to meet Malaysia’s new medical cannabis standards

• The country joins a growing list of Asian nations cautiously adopting medical cannabis frameworks anchored in pharmaceutical evidence and strict quality control

March 2025

As of 2025, Malaysia maintains strict drug laws under the Dangerous Drugs Act 1952, imposing death or life imprisonment for trafficking, severe penalties for possession, and tight controls on medical cannabis research and licensing.

Full Article Here ⬇️

Health Ministry opens door for Cannabis-based products in medical treatment: Kuala Lumpur, Malaysia 🇲🇾

https://www.thestar.com.my/news/nation/2025/03/04/health-ministry-opens-door-for-cannabis-based-products-in-medical-treatment?utm_source=chatgpt.com

16/10/2025

New Cannabis Analog Outperforms Morphine: Pre-Clinical

Previous Post on VER-01 a full spectrum cannabis extract showing efficacy and safety profile superior to traditional opiates. (3rd Phase Clinical Trial)

Today’s Post MIRA-55 shows morphine-level pain relief + anti-inflammation effect in preclinical tests potential non-opioid analgesic breakthrough (Pre-Clinical)

✔️ Key Findings from the Study

• In a formalin inflammatory pain model, MIRA-55 reduced pain sensitivity ~3×, returning pain thresholds close to baseline

• Analgesic efficacy matched that of morphine in the same model

• No sedation or swelling was observed with MIRA-55 treatment

• The U.S. DEA determined MIRA-55 is not a controlled substance, removing a major regulatory barrier

• Earlier studies also showed MIRA-55 blocked thermal and mechanical hyperalgesia without increasing inflammation, while low-dose THC exacerbated inflammation in similar tests

✔️ Mechanistic Profile & Design

• MIRA-55 is a synthetic analog engineered to selectively activate CB2 receptors (pain + anti-inflammatory) with minimal CB1 activity (psychoactive)

• It offers a favorable pharmacological balance: higher efficacy at both CB1 and CB2 compared to THC, with sustained agonist activity across increasing doses

✔️ Implications & Outlook

• If translation to humans holds, MIRA-55 could become a much safer alternative to opioids for chronic inflammatory pain

• The non-controlled status accelerates the path to clinical trials and reduces regulatory complexity

• Next steps include filing an IND and initiating human safety / efficacy trials

✔️ Nearly 60% of modern medicines are derived or inspired by nature, with plants, fungi, and marine organisms providing the molecular blueprints for today’s most effective drugs.

Strict scheduling 1 of natural Cannabis blocks and create prohibiting regulation for RnD, pushing pharma to design synthetic analogs instead of developing real plant-based medicines.

✔️ Despite discovering the endocannabinoid system over 30 years ago, a master regulator of pain, mood, and immunity, most universities still offer no formal courses on it, while pharmaceutical companies quietly advance synthetic cannabinoid analogs to exploit its untapped therapeutic potential.

October 16, 2025

Mira Pharmaceuticals press release on preclinical data for MIRA-55 and Article Here ⬇️

MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Ma*****na Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks.

https://mirapharmaceuticals.com/mira-reports-potent-inflammatory-pain-relief-from-non-psychoactive-ma*****na-analog-mira-55-in-animal-model-matching-morphine-without-opioid-risks/

15/10/2025

Global Cannabis Market Growth 2025-2033

• The global cannabis market is forecasted to soar from USD 39.1 billion (2024) to USD 151.7 billion (2033)

• Expected compound annual growth rate (CAGR) ≈ 16.26 %

✔️ Key Growth Drivers

• Expanding legalization across regions, from North America and Europe to Asia, including Thailand’s evolving prescription model

• Rising acceptance of cannabis-based treatments for chronic pain, epilepsy, nausea, inflammation, and opioid-replacement therapy

• Surge in wellness and nutraceutical demand, especially CBD-rich formulations

• Rapid product diversification: edibles, beverages, tinctures, topicals, and minor-cannabinoid concentrates

• Investment acceleration due to regulatory clarity and consumer normalization

✔️ Challenges

• Regulatory inconsistency and cross-border compliance burdens

• Illicit-market price pressure undermining licensed producers

• Need for GACP - GMP-level manufacturing, validated QC testing, and reliable analytical standards

✔️ Strategic Opportunities

• High-purity extracts and minor-cannabinoid innovations will define the next growth wave

• Labs mastering chromatographic purification, solvent recovery, and metabolomic fingerprinting gain strong competitive edge

• Long-term success hinges on standardization + scientific evidence + regulatory trust

✔️ Global Outlook

• By 2033 cannabis will emerge as one of the fastest-growing botanical economies, linking agriculture, biotechnology, and pharmaceutical R&D into a unified global health industry.

✔️ Cannabis, Kratom, and Psychedelics, once ancient traditional medicines, are now being modernized through science and regulation to enhance safety, efficacy, and standardization, paving the way for next-generation therapeutics in pain relief and mental health care.

From Plants - Patents - to Pharmaceuticals

Link to source here ⬇️

October 15, 2025

https://www.pharmiweb.com/press-release/2025-10-14/cannabis-market-forecast-report-2025-2033-increasing-consumer-demand-new-medicinal-uses-and-chang

07/10/2025

Cannabis-Based Drug Outperforms Opioids in Major Pain Trial

• A new pharmaceutical derived from Cannabis sativa called VER-01 has shown superior results to opioids in treating chronic low back pain in a Phase 3 clinical trial involving more than 800 patients

• Participants taking VER-01 reported a significant 3-point reduction in pain intensity on a 10-point scale over 12 weeks with improvements in sleep quality physical function and overall quality of life

• Unlike opioids VER-01 caused fewer side effects such as constipation and did not show risks of dependence or respiratory suppression

• The formulation is standardized and low in psychoactive THC focusing instead on therapeutic cannabinoids with potent analgesic and anti-inflammatory actions

• Researchers noted patients maintained pain relief for up to a year in extended studies suggesting sustained benefit and improved tolerability over traditional opioid therapy

• This success positions VER-01 as a potential game changer in pain management offering effective relief without the addiction and overdose risks of opioids

• The results also strengthen the global case for pharma-grade cannabinoid medicines produced under GMP standards with precise dosing and analytical quality control

• As the opioid crisis continues this innovation highlights how plant-based therapeutics can deliver safer long-term solutions while advancing evidence-based acceptance of cannabis-derived drugs in mainstream medicine

✔️ A future where cannabinoids replace opioids in chronic pain care is no longer hypothetical it is becoming scientifically validated

Oct 07, 2025

Link to article here ⬇️ FORBES

https://www.forbes.com/sites/sarahsinclair/2025/10/07/cannabis-based-drug-works-better-than-opioids-could-it-change-how-we-treat-pain/

06/10/2025

The Lazy Stoner Myth: What Science Really Shows About Cannabis and Motivation

✔️ Study Overview

• Researchers examined whether regular cannabis users truly experience impaired brain control or reduced motivation, the scientific foundation behind the “lazy stoner” stereotype

• The study compared 30 regular cannabis users and 30 non-users using functional near-infrared spectroscopy (fNIRS) to measure prefrontal and orbitofrontal brain activity

• Participants completed three standardized cognitive tests

- Go/No-Go Task: measures ability to stop an automatic response

- Stop-Signal Task: evaluates quick impulse inhibition

- Cannabis Stroop Task: detects attention bias toward cannabis-related cues

✔️ Key Findings

• No significant differences in behavior, attention, or brain activation between cannabis users and non-users

• Prefrontal cortex activity, responsible for focus, decision-making, and motivation, was normal in regular users

• Cannabis use history (frequency or duration) showed no correlation with cognitive or neural outcomes

✔️ What This Means

• The stereotype that cannabis makes people “lazy” or unmotivated is not supported by evidence for moderate, non-dependent users

• Cognitive control and attention remain intact in regular users who are not dependent

• Brain imaging confirms normal inhibitory control, meaning motivation and discipline circuits are working as efficiently as in non-users

✔️ Why It Matters

• This research helps dismantle outdated stigma that paints all cannabis users as unproductive or disengaged

• It emphasizes the importance of dose, dependency, and context, occasional or moderate cannabis use is not the same as chronic heavy use

• For policymakers and health professionals, the data highlight the need for evidence-based narratives, not fear-based assumptions

✔️ Final Takeaway

Science shows that moderate cannabis use does not blunt motivation or cognitive control
The “lazy stoner” image is cultural fiction, not neuroscience.

Not all cannabis cultivars are equal, each produces distinct effects based on cannabinoid and terpene profiles. Some uplift mood, boost focus, or ease pain, while others relax muscles, reduce anxiety, or promote deep sleep.

October 2, 2025

Source to study here ⬇️

No differences in neural responses or performance during cannabis cue-specific inhibitory control tasks between recreational cannabis users and non-users: Insights from fNIRS.

https://journals.sagepub.com/doi/full/10.1177/02698811251358814

03/10/2025

Another Newly Discovered Cannabis Compound.

✔️ Scientists have discovered a new cannabis compound called Cannabizetol (CBGD)

• Identified as a rare methylene bridged dimeric cannabinoid isolated from Cannabis sativa and confirmed by advanced synthesis methods

• Shows remarkable antioxidant activity, protecting skin cells against oxidative stress by reducing reactive oxygen species

• Demonstrates strong anti inflammatory effects in skin models by downregulating key inflammatory cytokines including IL-6 and TNF-α

• Activity is significantly stronger compared to cannabitwinol (CBDD) a previously known dimeric cannabinoid

• Validated using continuous flow synthesis, enabling reliable production for research and potential dermatological applications

• Potential to become a novel bioactive metabolite for skincare formulations and pharmaceutical development targeting skin inflammation and oxidative stress

Cannabizetol (CBGD), the newly identified dimeric cannabinoid, shows stronger antioxidant and anti-inflammatory effects than vitamin C, E, and CBD, positioning it as a promising next-generation dermatological active.

✔️ Traditional medicine is being unlocked as modern science reveals complex cannabis compounds with therapeutic potential still waiting to be fully discovered and developed

Over the past two years, researchers uncovered new cannabis compounds: Cannabizetol (2025, antioxidant/anti-inflammatory), Cannabielsoxa (2025, novel cannabinoid), Epicannabidiol Hydrate (2024, CBD derivative), and flavoalkaloids/phenolics (2025, cannabis leaves), highlighting cannabis still-expanding chemical diversity.

Cannabis compounds vary by cultivar and environment. Preserving regional landraces under diverse conditions is essential to maintain genetic and chemical diversity for future research and therapeutic innovation.

Area 420 MALTA
Megan Mathew Legalise Cannabis Advocate NSW
เขียนอนาคตกัญชาไทย
Cannabis Fiji
Teacher Peter

Source to study here ⬇️

Cannabizetol, a Novel Cannabinoid: Chemical Synthesis, Anti-inflammatory Activity and Extraction from Cannabis sativa L

https://pubs.acs.org/doi/10.1021/acs.jnatprod.5c00826

01/10/2025

STRESS is one of the most well-documented “Silent Drivers” of disease. Both acute stress (short-term fight-or-flight) and chronic stress (long-lasting activation of the hypothalamic-pituitary-adrenal [HPA] axis and sympathetic nervous system) can affect nearly every organ system.

Stress is not just “Mental.” It alters the Brain, Immune, Cardiovascular, Endocrine, Digestive, and Reproductive Systems. Chronic stress is now recognized as a causal risk factor in many top global killers (Heart Disease, Diabetes, Stroke, Depression, Neurodegeneration, Cancer progression).

Those who can reduce or eliminate STREES through safely using Medicinal Cannabis, can avoid many expensive medications, preventing listed of diseases, leading a higher quality of life. Always, speak to a medical professional before taking new and or combined medications, including cannabis.

Source to stress study link here ⬇️

https://pmc.ncbi.nlm.nih.gov/articles/PMC5137920/

Green Culture Labs co., Ltd

03/11/2025

30/10/2025

25/10/2025

24/10/2025

22/10/2025

22/10/2025

16/10/2025

15/10/2025

07/10/2025

06/10/2025

03/10/2025

01/10/2025

ที่อยู่

เว็บไซต์

แจ้งเตือน

ทางลัด

แชร์

ประเภท